Stocktoria
Longeveron Inc. LGVN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-02-12
Longeveron Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 67.0% | 78.8% | 31.2% | 40.7% | 45.2% |
| Operating margin | -1942.2% | -690.7% | -2966.0% | -1476.5% | -1336.6% |
| Net margin | -1893.6% | -667.8% | -3020.2% | -1541.3% | -1305.1% |
| FCF margin | -1575.5% | -607.1% | -2722.6% | -1189.7% | -763.1% |
| Return on assets | -221.3% | -62.5% | -177.3% | -68.7% | -39.9% |
| Return on equity | -400.1% | -73.0% | -317.7% | -91.9% | -45.5% |
| Current ratio | 1.33 | 7.60 | 1.50 | 4.17 | 13.06 |
| Revenue growth | -49.9% | 237.4% | -42.0% | -6.4% | -76.8% |
Source: SEC EDGAR filings · CIK 0001721484 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.